CLEVELAND, Sept. 6 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(Boston Stock Exchange:CFB), today announced that it has received a $750,000 Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) for the development of small molecule radioprotectors. Radioprotectors are substances, which reduce damage produced by radiation exposure to healthy cells.

The NCI contract will further strengthen the Company's development program for radioprotectors by funding its preclinical research of radioprotective agents acting via a new mechanism, as recently described in Nature Chemical Biology

Michael Fonstein, Ph.D., Chief Executive Officer of Cleveland BioLabs, stated, "We are very pleased to receive a highly competitive Phase II contract award from the National Cancer Institute. This contract is further validation of the results from our Phase I study and demonstrates the significant need and substantial market opportunities for this technology. Our first radioprotector is in late stage development for use in defense and anti-terrorism applications."

Dr. Andrei Gudkov, Cleveland BioLabs Chief Scientific Officer, added, "Our approach to developing radioprotectors is based on the discovery of ways to pharmacologically modulate most basic mechanisms of the cellular response to a variety of stresses, including programmed cell death. This should enable us to extend our research to develop drugs that reduce severe side effects of chemo- and radiotherapy for tumors by selective protection of healthy tissues. Our technology has the potential to improve the quality of life for millions of cancer patients."

The Company's first radioprotector, Protectan CBLB502, is in the late stages of development for the treatment of acute radiation syndrome, which results from exposure to high levels of radiation following a nuclear or radiological incident. Protectan CBLB502 is a modified protein of a microbe that protects cells from apoptosis. It has shown efficacy in protection against lethal doses of radiation in rodents and non-human primates. Other applications for its use include protection from cancer treatment side effects.

Cleveland BioLab's other advanced drug candidate, Curaxin CBLC102, is a small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has received approval to initiate Phase II trials with CBLC102 in hormone refractory prostate cancer.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company with the goal to identify and develop new types of drugs for the protection of normal tissues from exposure to radiation and other stresses and for cancer treatment. Our development efforts are based on discoveries made in connection with the investigation of the cell-level process known as apoptosis. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements that reflect our current view with respect to various aspects of the events described above. Actual results could be significantly different. Factors that could affect results include those set forth in filings made by Cleveland BioLabs, Inc. with the Securities and Exchange Commission. These factors include, but are not limited to, those discussed in our Registration Statement on Form SB-2 under the caption "Risk Factors." We caution readers not to place undue reliance on these forward-looking statements. Although forward-looking statements help provide complete information about future prospects, readers should keep in mind that forward-looking statements are much less reliable than historical information.

     The Global Consulting Group
     Rachel Levine
     T: (646) 284-9439